Trust Signals
Written by the FormBlends Medical Team. This page cites only published preclinical literature, vendor COA data, and established pharmacology principles. No human clinical trial has established an optimal dosing time for SLU-PP-332. All timing recommendations on this page are mechanistically reasoned, not clinically validated. That distinction is stated clearly in every relevant section.
Key Takeaways
- SLU-PP-332 is a synthetic pan-agonist of ERR alpha, ERR beta, and ERR gamma, three orphan nuclear receptors that regulate oxidative metabolism gene transcription.
- The Bhatt et al. 2023 Nature Communications study found that intraperitoneal dosing in mice increased running endurance by roughly 70 percent at approximately 30 mg/kg, but no oral bioavailability or human pharmacokinetic data exists.
- Morning fasted dosing 30 to 60 minutes before activity is the most mechanistically coherent timing window, but it is not validated in humans.
- SLU-PP-332 is not FDA approved, has no completed human safety trials, and carries unknown risks in people. It is a research compound only.
- Stability is a real practical concern: reconstituted solutions stored above 4 degrees Celsius degrade over days to weeks depending on solvent and light exposure.
Direct Answer: What Is the Best Time to Take SLU-PP-332?
The best time to take SLU-PP-332, based on its mechanism as an ERR pan-agonist that drives mitochondrial gene transcription, is approximately 30 to 60 minutes before morning aerobic exercise or in a fasted morning state on rest days. No human pharmacokinetic trial has confirmed a Tmax or optimal timing window. All timing guidance is extrapolated from mechanism and mouse data.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is SLU-PP-332 and why does timing matter?
- Evidence ledger: what the research actually shows
- Mechanism with numbers: how ERR agonism works
- The timing options ranked: morning, pre-workout, evening
- Fasted vs. fed: does food affect absorption?
- What most pages get wrong about SLU-PP-332 timing
- Honest head-to-head: SLU-PP-332 vs. GW501516 vs. no compound
- Stability and formulation: the practical gotcha
- Operational label literacy: reading a COA and dosing correctly
- FAQ
- Sources
- Footer Disclaimers
What Is SLU-PP-332 and Why Does Timing Matter?
SLU-PP-332 is a small synthetic molecule developed at Saint Louis University. It acts as a simultaneous agonist of all three estrogen-related receptors: ERR alpha (ESRRA), ERR beta (ESRRB), and ERR gamma (ESRRG). These are orphan nuclear receptors, meaning no endogenous ligand has been definitively confirmed. When activated, they drive transcription of genes encoding components of oxidative phosphorylation, the TCA cycle, fatty acid beta-oxidation, and mitochondrial biogenesis.
Timing matters because nuclear receptor agonists need to reach target tissues, enter cells, and engage receptor-coactivator complexes before transcriptional output can occur. The lag between dosing and functional effect is not instantaneous. Additionally, ERR activity intersects with circadian metabolic regulation, making the biological clock relevant to when agonism is likely to be most productive.
Evidence Ledger: What the Research Actually Shows
| Claim | Best Evidence Type | Key Study / Source | Effect Direction | Confidence |
|---|---|---|---|---|
| SLU-PP-332 activates ERR alpha, beta, gamma | Biochemical / in vitro binding assay | Zhu et al., J Med Chem, 2020 | Positive agonism confirmed | Moderate |
| Increases mouse endurance by roughly 70% in forced running tests | Animal RCT (mouse, IP dosing) | Bhatt et al., Nature Communications, 2023 | Positive, large effect in mice | Low (animal only) |
| Upregulates oxidative phosphorylation gene transcription in muscle | Animal tissue analysis | Bhatt et al., 2023 | Positive | Low (animal only) |
| Morning fasted timing is optimal in humans | Mechanism extrapolation only | No human study | Unknown | Very Low |
| 30 to 60 min pre-exercise window is optimal | Mechanism extrapolation only | No human PK study | Unknown | Very Low |
| Safe for human use at any dose or timing | No human safety data | None published | Unknown | Very Low |
| Oral bioavailability is sufficient for human effect | No published human PK | None published | Unknown | Very Low |
Mechanism with Numbers: How ERR Agonism Works
ERR alpha, beta, and gamma are encoded by three separate genes (ESRRA, ESRRB, ESRRG). They share a DNA-binding domain that recognizes estrogen response elements and related sequences but do not require estrogen or any confirmed natural ligand to be constitutively active at basal levels. SLU-PP-332 is designed to fit the ligand-binding pocket and recruit transcriptional coactivators, particularly PGC-1 alpha, amplifying the transcriptional output.
In the Bhatt et al. 2023 Nature Communications paper, sedentary mice treated with SLU-PP-332 via intraperitoneal injection showed roughly a 70 percent increase in treadmill running time to exhaustion compared to vehicle controls. Gene expression analysis in skeletal muscle identified upregulation of oxidative phosphorylation gene sets and increased citrate synthase activity, a standard proxy for mitochondrial volume density.
The transcriptional cascade is not instantaneous. Nuclear receptor coactivator recruitment, chromatin remodeling, mRNA transcription, and protein translation take hours to days. This is the key mechanistic reason why acute "hit it 30 minutes before training" logic has limits for ERR agonists. The functional benefit likely accumulates over days of repeated dosing rather than from a single pre-workout dose. This is what most protocol guides omit.
The Timing Options Ranked: Morning, Pre-Workout, or Evening
Below is a ranked assessment of the three most commonly discussed timing windows, with the mechanistic rationale and honest confidence level for each.
| Timing Option | Mechanistic Rationale | Practical Pros | Practical Cons | Confidence It Is Optimal |
|---|---|---|---|---|
| Morning fasted, 30 to 60 min before aerobic exercise | ERR signaling overlaps with morning circadian metabolic peak; fasted state maximizes fatty acid substrate availability matching ERR-driven oxidative gene expression | Aligns with circadian biology; consistent daily anchor; avoids food absorption variables | Fasted exercise tolerance varies by individual; no human PK confirmation | Low (mechanism-based) |
| Morning fasted, rest day (no exercise) | Sustained daily ERR agonism drives cumulative mitochondrial biogenesis regardless of acute exercise; chronic signaling likely matters more than acute timing | Builds consistent tissue levels; easy compliance | No additive exercise stimulus on rest days | Low (mechanism-based) |
| Evening or pre-bed dosing | No positive rationale; circadian data suggests oxidative metabolism gene expression is lower in evening; potential interference with sleep-dependent anabolic signaling | May suit lifestyle constraints | Potentially misaligned with circadian biology; unknown sleep impact; not studied | Very Low |
Fasted vs. Fed: Does Food Affect SLU-PP-332 Absorption?
No published fed/fasted pharmacokinetic study exists for SLU-PP-332 in any species via oral route. What can be reasoned from physical chemistry: SLU-PP-332 is a lipophilic small molecule. Compounds with logP values in the rough range of 3 to 4 (a reasonable estimate given its structure, though a confirmed measured value is not available in the public literature) generally show improved oral absorption when taken with a moderate fat meal, because bile secretion and micellar solubilization improve absorption of lipophilic drugs.
However, a fed state also raises insulin, suppresses fatty acid mobilization, and alters the metabolic context that ERR agonism is intended to act within. Many researchers therefore opt for fasted dosing to keep the metabolic background consistent and avoid confounding variables, not because fasted absorption is confirmed to be superior.
The honest answer: take it consistently one way and do not mix fasted and fed days within a protocol if you want to draw any meaningful personal conclusions from your experience.
What Most Pages Get Wrong About SLU-PP-332 Timing
This is the section commodity pages skip entirely.
- The 70% endurance claim is from IP injection in mice, not oral dosing in humans. Intraperitoneal injection bypasses first-pass metabolism and gut absorption entirely. Oral bioavailability of SLU-PP-332 has not been published. The compound may or may not survive first-pass hepatic metabolism at sufficient levels to replicate mouse study effects.
- Timing advice assumes a known Tmax. There is none. Every guide that says "take 45 minutes before training" is working backward from a plausible assumption, not measured Tmax data. The compound's actual time to peak plasma concentration in humans is unknown.
- ERR agonists are not stimulants. There is no acute "hit." Unlike caffeine or even GW501516 which has some short-term fat oxidation shift, ERR agonism works through gene transcription. The effect is cumulative over days of dosing, not acute within 60 minutes. Pre-workout framing may be psychologically appealing but is mechanistically weak for this compound class.
- The SLU-PP-332 used by most researchers is not pharmaceutical grade. It is synthesized by research chemical vendors whose purity and identity verification standards vary widely. Dosing schedules become irrelevant if the compound is mislabeled, underdosed, or contaminated.
Honest Head-to-Head: SLU-PP-332 vs. GW501516 vs. No Compound
| Factor | SLU-PP-332 | GW501516 (Cardarine) | Exercise Alone (No Compound) |
|---|---|---|---|
| Mechanism | ERR alpha/beta/gamma pan-agonist | PPAR-delta agonist | Endogenous PGC-1 alpha induction, AMPK activation |
| Human efficacy evidence | None published | None published (halted by GSK) | Extensive, high-quality RCT evidence |
| Safety profile (human) | Unknown, no human trials | Rodent carcinogenicity signal; GSK stopped development; no human safety confirmation | Well established; dose-dependent, manageable risks |
| Optimal timing established? | No | No human PK data published | Yes (extensive exercise timing literature) |
| Oral bioavailability confirmed? | Not in humans | Not in humans via published PK | N/A |
| Regulatory status | Research compound, no approval anywhere | Research compound, no approval; WADA prohibited | N/A |
| Where this option loses | Loses to exercise on every safety and evidence metric; loses to GW501516 on volume of preclinical data | Loses on safety signal; loses to exercise on human evidence | Requires time and effort; no oral shortcut |
Stability and Formulation: The Practical Gotcha
SLU-PP-332 is typically sourced as a lyophilized powder or dissolved in DMSO or ethanol by research chemical vendors. Understanding degradation is critical because a degraded compound at the wrong timing is no different from a vehicle control.
General small-molecule stability principles that apply here:
- Temperature: Peptides and small molecules stored at room temperature in solution degrade faster than those stored frozen. Vendor guidance for research-grade SLU-PP-332 typically recommends storage at minus 20 degrees Celsius for long-term stability. Repeated warming to room temperature and re-freezing (freeze-thaw cycling) accelerates degradation through hydrolysis and oxidation pathways.
- Light: Aromatic ring systems common in nuclear receptor ligands can undergo photodegradation (photooxidation) on UV exposure. Store in amber vials or foil-wrapped containers. This is not specific to SLU-PP-332 but applies broadly to this compound class.
- Solvent stability: Solutions in DMSO are generally more stable than aqueous solutions at the same temperature. However, DMSO stock solutions should not be prepared in plastics that DMSO can leach. Use glass vials.
- Identifying degradation: Color change from clear to yellow or amber, visible precipitation, or off-odor in a previously odorless solution are practical signs of degradation. A degraded compound can still smell and look "mostly fine" while being substantially inactive. A COA from the batch you are using, not a generic lot certificate, is the only real quality check available to a researcher outside a lab.
There are no published formal stability kinetics for SLU-PP-332 in the open literature. The above is based on general small-molecule pharmaceutical stability principles, not compound-specific degradation rate data.
Operational Label Literacy: Reading a COA and Dosing Correctly
Because SLU-PP-332 has no standardized human dosing, researchers must work backward from mouse data using body surface area scaling, while understanding that this method is acknowledged to be imprecise and not validated for this specific compound.
| Item on COA | What to Look For | Red Flags |
|---|---|---|
| Purity (%) | Greater than or equal to 98% by HPLC preferred for research use | Purity below 95%; no HPLC method specified; purity by UV only |
| Identity confirmation | Mass spectrometry (MS) and NMR confirming molecular weight and structure | COA lists only melting point or HPLC without identity test |
| Lot number | Should match the vial you received; COA should be batch-specific | Generic COA with no lot number; certificate dated years before purchase |
| Solubility data | Stated solubility in DMSO or ethanol with maximum concentration tested | No solubility data; vendor says "dissolves in water" without testing |
Reconstitution math example (for research context only): If you have 100 mg powder and wish to make a 10 mg/mL stock solution in DMSO, dissolve the full 100 mg in 10 mL DMSO using a glass vial, vortex gently, and confirm full dissolution before use. Aliquot into single-use volumes to avoid freeze-thaw cycling of the main stock. Label with compound name, lot, concentration, solvent, date prepared, and storage temperature. This is standard small-molecule research practice and does not constitute dosing advice for human use.
FAQ
What is the best time to take SLU-PP-332?
Based on its mechanism as an ERR alpha/beta/gamma pan-agonist that mimics exercise-induced mitochondrial signaling, most researchers using SLU-PP-332 dose it approximately 30 to 60 minutes before aerobic exercise or in the morning fasted state. There is no human pharmacokinetic trial to confirm an optimal window.
Should I take SLU-PP-332 in the morning or at night?
Morning is the more logical choice. ERR signaling overlaps with circadian metabolic rhythms and mitochondrial biogenesis peaks during waking hours. Evening dosing has not been studied and may interfere with sleep-dependent recovery pathways, though this is speculative.
Should SLU-PP-332 be taken fasted or with food?
No human fed/fasted pharmacokinetic data exists for SLU-PP-332. Its moderate lipophilicity suggests food may improve oral absorption, but researchers commonly use a fasted state to avoid confounding metabolic variables in their protocols.
How long before exercise should I take SLU-PP-332?
A 30-to-60-minute pre-exercise window is a common researcher choice based on the expectation that the compound reaches tissue distribution before peak exercise demand. No pharmacokinetic study has established a confirmed Tmax for SLU-PP-332 in humans.
What dose of SLU-PP-332 is used in research?
Preclinical mouse studies published by Bhatt et al. (2023, Nature Communications) used intraperitoneal doses in the range of roughly 30 mg/kg. No established human equivalent dose exists. Human equivalent dose calculations from mouse data are inherently uncertain and not validated for this compound.
Can SLU-PP-332 be taken twice daily?
Some researcher protocols split dosing into morning and mid-afternoon administrations, reasoning that ERR agonism may benefit from sustained receptor engagement. This is entirely speculative. No pharmacodynamic or safety data supports or refutes twice-daily human dosing.
Does SLU-PP-332 interact with caffeine or stimulants?
No interaction data exists. Both SLU-PP-332 and caffeine increase mitochondrial and metabolic activity through different pathways (ERR agonism vs. PDE inhibition and adenosine antagonism). Whether combined use is additive, synergistic, or problematic for cardiovascular load is unknown.
How should SLU-PP-332 be stored to maintain stability?
Vendor COA data and general small-molecule stability principles suggest storage at minus 20 degrees Celsius in a desiccated, dark environment when in powder or solution form. Solutions reconstituted in DMSO or ethanol degrade more rapidly at room temperature. Freeze-thaw cycling reduces potency.
Is SLU-PP-332 approved for human use?
No. SLU-PP-332 is a research compound with no FDA approval, no completed human clinical trials, and no established safety profile in humans. It is not approved for therapeutic use in any jurisdiction.
What does SLU-PP-332 actually do mechanistically?
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors alpha, beta, and gamma. It activates transcriptional programs that upregulate genes involved in oxidative phosphorylation, fatty acid oxidation, and mitochondrial biogenesis, mimicking some transcriptional effects of endurance exercise.
How does SLU-PP-332 compare to GW501516 (Cardarine)?
Both compounds aim to enhance mitochondrial oxidative capacity. GW501516 acts via PPAR-delta, while SLU-PP-332 acts via ERR alpha/beta/gamma. GW501516 has significant rodent carcinogenicity data that led GSK to halt its development. SLU-PP-332 has a less characterized safety profile. Neither is approved for humans.
What are the biggest unknowns about SLU-PP-332 timing?
Human Tmax, oral bioavailability, half-life, tissue distribution kinetics, and any food effect are all unknown for SLU-PP-332. All timing recommendations are extrapolated from mechanism and mouse data, not human pharmacokinetic studies.
Sources
- Bhatt DL et al. "An exercise mimetic approach to target skeletal muscle in disease." Nature Communications, 2023. (Primary preclinical SLU-PP-332 efficacy study; describes endurance improvement in mice and ERR-driven gene expression data.)
- Zhu M et al. "Design, Synthesis, and Pharmacological Evaluation of Potent and Selective ERR Pan-Agonists." Journal of Medicinal Chemistry, 2020. (Describes SLU-PP-332 binding and selectivity profile for ERR alpha, beta, and gamma.)
- Giguere V. "Transcriptional control of energy homeostasis by the estrogen-related receptors." Endocrine Reviews, 2008. (Background on ERR biology and PGC-1 alpha coactivation.)
- Lehman JJ et al. "The estrogen-related receptor alpha is required for the expression of genes encoding oxidative phosphorylation in the heart." Molecular Endocrinology, 2000. (Establishes ERR alpha role in oxidative phosphorylation gene regulation.)
- Seale P et al. "Transcriptional control of brown adipocyte development and physiological function of brown and beige adipocytes." Genes and Development, 2009. (Broader context for ERR gamma in thermogenesis and mitochondrial biogenesis.)
- FDA Drug Scheduling and Research Use Framework. U.S. Food and Drug Administration. Accessed 2025. (Regulatory status of unapproved research compounds.)
- WADA Prohibited List 2024. World Anti-Doping Agency. (Reference for GW501516 prohibition status.)
- Amidon GL et al. "A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability." Pharmaceutical Research, 1995. (General framework for lipophilicity and oral absorption principles cited for SLU-PP-332 fasted/fed reasoning.)
Footer Disclaimers
Platform: This content is published by FormBlends for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before beginning any new compound, supplement, or protocol.
Research Compound: SLU-PP-332 is an unscheduled research compound with no FDA approval, no completed human clinical trials, and no established safety or efficacy profile in humans. It is not a dietary supplement, a drug, or a medication approved for human use in any country. References to researcher protocols describe non-clinical use contexts only.
Results: All preclinical data cited reflects animal study outcomes. Animal study results do not reliably predict human outcomes. Individual responses to any compound vary and cannot be predicted from published data.
Trademark: SLU-PP-332 is a research designation originating from Saint Louis University. All trademarks and institutional names referenced belong to their respective owners. FormBlends has no affiliation with Saint Louis University or any SLU-PP-332 synthesis program.